Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07827768). This is a study registration, not published results. Lead sponsor: Institute for Molecular Medicine. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 160 participants (ESTIMATED). Conditions: Preclinical Alzheimer's Disease, Alzheimer Disease. Interventions: BIOLOGICAL: AV-1959R; DRUG: Placebo. Primary outcome measures: Incidence of Treatment-Emergent Adverse Events (TEAEs) , From first study intervention through Week 78; Incidence of ARIA-E and ARIA-H , Through Week 78; Clinically Significant Changes in Safety Assessments , Through Week 78; Change From Baseline in C-SSRS Score , Baseline through Week 78; Serum Anti-Amyloid-Beta Antibody Levels , Baseline through Week 78. Brief summary: This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease. Approximately 160 participants will be randomized to receive AV-1959R or placebo and will be followed for 78 weeks. The study will assess safety, immune responses, brain amyloid, and Alzheimer's disease-related biomarkers.